Alarming Rise of Primary HIV Drug Resistance in Major Regions of Russia.

IF 0.8 4区医学 Q4 IMMUNOLOGY

Current HIV Research Pub Date : 2023-01-01 DOI:10.2174/011570162X271430231201075335

Dmitry Kireev, Alina Kirichenko, Aleksey Lebedev, Marina Bobkova

{"title":"Alarming Rise of Primary HIV Drug Resistance in Major Regions of Russia.","authors":"Dmitry Kireev, Alina Kirichenko, Aleksey Lebedev, Marina Bobkova","doi":"10.2174/011570162X271430231201075335","DOIUrl":null,"url":null,"abstract":"Objective: The study aimed to compare the prevalence of surveillance HIV drug resistance mutations (SDRMs) across the main federal districts of Russia.Methods: A pooled analysis was conducted to examine data on HIV primary drug resistance (HIV PrimDR). The analysis was based on published results primarily from Russian regional clinical and scientific laboratories, covering a span of 20 years.Results: The findings indicate that three surveyed regions, namely Central, Far Eastern, and Volga, exhibit a low level of HIV PrimDR prevalence (not exceeding 5%), and this prevalence does not show a tendency to increase. In contrast, three major regions, namely Northwestern, Southern, and Siberian, demonstrate a significant and progressive increase in HIV PrimDR prevalence, with recent values surpassing 10%.Conclusion: Consequently, it was concluded that a change in the HIV treatment strategy in these regions is imperative, emphasizing the need to expedite the transition to the utilization of secondgeneration integrase inhibitors.","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"347-353"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/011570162X271430231201075335","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The study aimed to compare the prevalence of surveillance HIV drug resistance mutations (SDRMs) across the main federal districts of Russia.

Methods: A pooled analysis was conducted to examine data on HIV primary drug resistance (HIV PrimDR). The analysis was based on published results primarily from Russian regional clinical and scientific laboratories, covering a span of 20 years.

Results: The findings indicate that three surveyed regions, namely Central, Far Eastern, and Volga, exhibit a low level of HIV PrimDR prevalence (not exceeding 5%), and this prevalence does not show a tendency to increase. In contrast, three major regions, namely Northwestern, Southern, and Siberian, demonstrate a significant and progressive increase in HIV PrimDR prevalence, with recent values surpassing 10%.

Conclusion: Consequently, it was concluded that a change in the HIV treatment strategy in these regions is imperative, emphasizing the need to expedite the transition to the utilization of secondgeneration integrase inhibitors.

查看原文本刊更多论文

俄罗斯主要地区原发性艾滋病毒耐药性惊人上升。

目的:本研究旨在比较俄罗斯主要联邦区监测HIV耐药突变(SDRMs)的流行情况。方法:采用汇总分析方法，对HIV原发性耐药(HIV PrimDR)数据进行分析。该分析主要基于俄罗斯地区临床和科学实验室发表的结果，涵盖了20年的时间。结果:中部、远东和伏尔加河3个调查地区的HIV PrimDR患病率较低(不超过5%)，且无上升趋势。相比之下，西北、南部和西伯利亚三个主要地区的HIV PrimDR患病率呈现出显著且逐步上升的趋势，最近的数值超过了10%。结论:因此，我们得出结论，改变这些地区的HIV治疗策略是必要的，强调需要加快过渡到第二代整合酶抑制剂的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current HIV Research 医学-病毒学

CiteScore

1.90

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.